环索奈德

Tier C · 观察 / 贸易

Ciclesonide

武田药品工业株式会社

原研

2004

首批上市

到期年（公开口径）

无销量数据

峰值销售

化学药

类型

靶点：GR

商品名：Omnaris、Omnaris HFA、Omnair、Osonase、Zetonna、Alvesco、Osonide、Zetonna/Omnaris/Alvesco、Alvesco HFA

适应症（已批准）：哮喘、常年性变应性鼻炎、季节性过敏性鼻炎、过敏性鼻炎

各地区研发/上市状态

美国

批准上市

2006-10-20

欧盟

无进展

2002-04-01

中国

批准上市

2012-12-11

日本

批准上市

2007-04-18

合成路线与中间体5 routes

原研路线 × 1优化路线（非专利）× 4工艺路线 × 0

路线按「原研路线 → 优化路线 / 工艺路线（非专利）」排序。每条路线附本站自绘的路线流程图（中间体 → 原料药）与中间体表（编号 / CAS / 英文名），可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染，未使用任何第三方路线图。

原研Route 1步骤 3 · 总收率 /

CICL-00113951-70-7CICL-00297-72-3CICL-003141700-34-7CICL-0042043-61-0CICL-005204444-45-1API · 环索奈德

编号	CAS 号	中间体名称
CICL-001	13951-70-7	(8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
CICL-002	97-72-3	isobutyric anhydride
CICL-003	141700-34-7	(8S,9S,10R,11S,13S,14S,16R,17S)-11-hydroxy-17-(2-(isobutyryloxy)acetyl)-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-16,17-diyl bis(2-methylpropanoate)
CICL-004	2043-61-0	cyclohexanecarbaldehyde
CICL-005	204444-45-1	2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl isobutyrate

优化Route 2步骤 2 · 总收率 /

CICL-00297-72-3CICL-0042043-61-0CICL-006638-94-8CICL-00778806-61-8API · 环索奈德

编号	CAS 号	中间体名称
CICL-002	97-72-3	isobutyric anhydride
CICL-004	2043-61-0	cyclohexanecarbaldehyde
CICL-006	638-94-8	(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
CICL-007	78806-61-8	2-((6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl isobutyrate

优化Route 3步骤 4 · 总收率 3.2 g

CICL-00113951-70-7CICL-00297-72-3CICL-0042043-61-0CICL-008—CICL-0091015172-34-5CICL-010161115-59-9API · 环索奈德

编号	CAS 号	中间体名称
CICL-001	13951-70-7	(8S,9S,10R,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
CICL-002	97-72-3	isobutyric anhydride
CICL-004	2043-61-0	cyclohexanecarbaldehyde
CICL-008	-	(6aR,6bS,7S,8aS,8bS,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
CICL-009	1015172-34-5	2-((6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate
CICL-010	161115-59-9	(6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one

优化Route 4步骤 2 · 总收率 18 g

CICL-0042043-61-0CICL-011—CICL-0121451396-66-9CICL-013996-30-5API · 环索奈德

编号	CAS 号	中间体名称
CICL-004	2043-61-0	cyclohexanecarbaldehyde
CICL-011	-	(8S,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
CICL-012	1451396-66-9	(6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-8b-(2-bromoacetyl)-10-cyclohexyl-7-hydroxy-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
CICL-013	996-30-5	sodium isobutyrate

优化Route 5步骤 3 · 总收率 /

CICL-0042043-61-0CICL-010161115-59-9CICL-011—CICL-01436609-97-9CICL-01579-30-1API · 环索奈德

编号	CAS 号	中间体名称
CICL-004	2043-61-0	cyclohexanecarbaldehyde
CICL-010	161115-59-9	(6aR,6bS,7S,8aS,8bS,10R,11aR,12aS,12bS)-10-cyclohexyl-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a-dimethyl-1,2,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-4H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4-one
CICL-011	-	(8S,11S,13S,14S,16R,17S)-11,16,17-trihydroxy-17-(2-hydroxyacetyl)-13-methyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one
CICL-014	36609-97-9	sodium cyclohexyl(hydroxy)methanesulfonate
CICL-015	79-30-1	isobutyryl chloride

常见问题（FAQ）

环索奈德的适应症有哪些？

已批准的适应症包括：哮喘、常年性变应性鼻炎、季节性过敏性鼻炎、过敏性鼻炎。

环索奈德的专利什么时候到期？

环索奈德的专利到期年暂无公开口径，本页会在数据管道核实后更新。

环索奈德有几条合成路线？

本站收录 5 条合成路线，最短路线 2 步、总收率 /。每条路线的中间体均带登记编号与 CAS 号。

环索奈德的关键中间体在哪里可以采购？

环索奈德路线中的中间体均已建立 CAS 档案，可直接按 CAS 发起询价，需求会进入供应网络撮合池。

如何获取环索奈德中间体的报价？

在本页选择目标中间体的 CAS 进入档案页，或在询价页直接提交需求；CAS 会自动带入供需撮合流程，由供应网络反馈报价。

数据来源：多源数据交叉核实（仅结构化字段） · 2026-09-27